Table 4.
Multivariate analysis
| Clinical characteristics or biomarker | Multivariable for NLR HR (95% CI); p value |
Multivariable for SII HR (95% CI); p value |
|---|---|---|
| NLR | ||
| <3.4 | 1.00 (ref) | |
| ≥3.4 | 1.40 (1.17–1.68); p < 0.001 | |
| SII | ||
| <831 | 1.00 (ref) | |
| ≥831 | 1.45 (1.20–1.75); p < 0.001 | |
| Age | 1.00 (0.99–1.01); p = 0.49 | 1.00 (0.99–1.01); p = 0.29 |
| ECOG-PS | ||
| 0 | 1.00 (ref) | 1.00 (ref) |
| 1 | 1.69 (1.40–2.04); p < 0.001 | 1.65 (1.37–2.00); p < 0.001 |
| 2 | 3.21 (2.19–4.71); p < 0.001 | 3.11 (2.12–4.56); p < 0.001 |
| 3 | 3.24 (1.02–10.27); p = 0.046 | 3.06 (0.97–9.71); p = 0.057 |
| Pre-treatment steroids | ||
| No | 1.00 (ref) | 1.00 (ref) |
| Yes | 1.23 (1.02–1.49); p = 0.033 | 1.25 (1.03–1.52); p = 0.021 |
| Bone metastases | ||
| No | 1.00 (ref) | 1.00 (ref) |
| Yes | 1.17 (0.97–1.43); p = 0.11 | 1.19 (0.98–1.45); p = 0.074 |
| Liver metastases | ||
| No | 1.00 (ref) | 1.00 (ref) |
| Yes | 1.79 (1.41–2.27); p < 0.001 | 1.76 (1.39–2.23); p < 0.001 |
| LDH | ||
| < Upper limit of normal | 1.00 (ref) | 1.00 (ref) |
| ≥ Upper limit of normal | 1.19 (0.95–1.48); p = 0.12 | 1.17 (0.94–1.46); p = 0.15 |
95% CI, 95% confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; n, number; NLR, neutrophil-to-lymphocyte ratio; RCC, renal cell carcinoma; SII, systemic immune-inflammatory index.